Novo Nordisk, the company behind blockbuster weight-loss drugs like Ozempic and Wegovy, had a deal with Hims & Hers that ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance coverage ...

Stock markets have rallied after U.S. President Donald Trump announced a ceasefire in the Israel-Iran conflict, although the ...

On Monday, major U.S. indices ended the day in the green with the Dow Jones Industrial Average rising 0.9% to 42,581.78, and the S&P 500 gaining nearly 1% to 6,025.17.

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

Rio Tinto, Hancock to Jointly Invest $1.6 Billion in Hope Downs 2 Project Rio Tinto said the development of the Hope Downs 2 project with Hancock Prospecting would involve two new pits that will churn ...

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...

The calming in the oil market came as several analysts said Iran would likely refrain from closing the waterway. Iran itself ...

Hims & Hers Health Inc.'s stock booked record losses Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with the telehealth ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims & Hers" or "the Company") (NYSE: ...